AI Drug Discovery
AI Drug Discovery
Building Better Medicines with AI
With 192 compounds and 67 validated assets in cellular models of disease across 12 therapeutic targets for multiple areas of biology, we're innovating at the intersection of data science, biology and drug development
With 192 compounds and 67 validated assets in cellular models of disease across 12 therapeutic targets for multiple areas of biology, we're innovating at the intersection of data science, biology and drug development
As Featured In
Model Medicines
Humanity Can’t Wait Decades, Which is Why We Focus on Days
We are focused on discovering drugs with best-in-class potential against rigorous target product profiles, not merely creating thousands of hits that never reach the clinic.
With GALILEO™, we've discovered 192 compounds and advanced 67 assets in cellular models of disease across 12 therapeutic targets for multiple areas of biology. Our data was validated by preeminent researchers and scientists at premier academic and corporate laboratories.
Therapeutic areas
Publications
Mar 20, 2025
Preprint
AmesNet: A Deep Learning Model Enhancing Generalization in Ames Mutagenicity Prediction
Mar 20, 2025
Preprint
AmesNet: A Deep Learning Model Enhancing Generalization in Ames Mutagenicity Prediction
Mar 20, 2025
Preprint
AmesNet: A Deep Learning Model Enhancing Generalization in Ames Mutagenicity Prediction
Jan 26, 2025
Preprint
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Jan 26, 2025
Preprint
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Jan 26, 2025
Preprint
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Load More
Load More
Load More
News & Events
Apr 2, 2025
Announcement
Model Medicines Advances AI-Driven Drug Safety Prediction with AmesNet™, Achieving Unprecedented Accuracy and Sensitivity in Mutagenicity Testing
Apr 1, 2025
Press
Model Medicines Featured on Bloomberg’s Vanguards of Health Care: Transforming Drug Discovery with AI
Apr 1, 2025
Events
Model Medicines CEO Daniel Haders II to Speak at Bloomberg's 4th Annual Generative AI Conference
Apr 2, 2025
Announcement
Model Medicines Advances AI-Driven Drug Safety Prediction with AmesNet™, Achieving Unprecedented Accuracy and Sensitivity in Mutagenicity Testing
Apr 1, 2025
Press
Model Medicines Featured on Bloomberg’s Vanguards of Health Care: Transforming Drug Discovery with AI
Apr 2, 2025
Announcement
Model Medicines Advances AI-Driven Drug Safety Prediction with AmesNet™, Achieving Unprecedented Accuracy and Sensitivity in Mutagenicity Testing
Apr 1, 2025
Press
Model Medicines Featured on Bloomberg’s Vanguards of Health Care: Transforming Drug Discovery with AI
PartnershipS
Validated by Leading Scientists at Top Academic and Corporate Labs
Our data is validated by preeminent researchers and scientists at premier academic and corporate laboratories.
We recognize that no one business can revolutionize the way medicines are discovered and developed on their own. We want to leverage our technology and expertise in partnership with the world’s leading researchers and scientists.
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research
We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Scripps Research
“We are very excited to partner with Model Medicines on this important endeavor to identify novel therapeutics to treat the immediate threat of SARS-CoV-2 today and prepare for the pandemics of tomorrow.”
Sumit Chanda, Ph.D
The Chanda Lab
A broad spectrum, orally available antiviral therapeutic with an extended half-life and a well documented safety and toxicity profile that can be administered on an outpatient basis is an extreme and urgent unmet medical need, which would be a game-changer in the global fight against COVID-19.
Adolfo Garcia-Sastre, Ph.D
Icahn School of Medicine at Mount Sinai
The Model Medicines-Scripps partnership has demonstrated that integrating artificial intelligence and machine learning models into the traditional High Throughput Screening drug discovery process can significantly improve the efficacy of drug discovery.
Arnab Chatterjee, Ph.D
Scripps Research